Margherita Ambrosini, Medical Oncologist at National Cancer Institute of Milan IRCCS Foundation, shared a post on LinkedIn:
“In this review, we delve into the key features of MSI-H/dMMR cancers, shedding light on current diagnostic challenges and the impact of immune checkpoint inhibitors across both advanced and early-stage disease.
Have a look!”
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb and Filippo Pietrantonio.
